Ocular Therapeutix, Inc. is a biotechnology company focused on the development of sustained-release therapies for retinal diseases. The company's primary product candidate is AXPAXLI (axitinib intravitreal hydrogel), also known as OTX-TKI, which is an investigational axitinib hydrogel administered via intravitreal injection. This therapy is currently in Phase 3 clinical trials for the treatment of wet age-related macular degeneration (AMD). Ocular Therapeutix also targets non-proliferative diabetic retinopathy (NPDR) and diabetic macular edema (DME) as areas for therapeutic expansion. The company utilizes hydrogel technology to reduce the therapeutic burden on patients, aiming to improve long-term adherence and vision preservation in conditions such as retinal vein occlusion and diabetic retinopathy.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Biotechnology Homepage ocutx.com
Sector Healthcare IR page investors.ocutx.com
Tags
retinal disease, sustained-release therapies, hydrogel technology, wet amd, diabetic retinopathy, diabetic macular edema, intravitreal injection, ophthalmology, AXPAXLI, OTX-TKI
Press page —

Metrics

Valuation  
Market cap $ 1.44B
Market cap (USD) $ 1.44B
P/E -4.55
PEG —
P/BV 3.27
P/S 28.59
P/OCF -5.69
P/FCF -5.39
Dividend yield —
Turnover / mcap —
Returns  
ROE -54.9%
ROI -36.6%
ROIC -27.9%
Profit margin -511.9%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 10.9%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 56
Quality score -82.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 51.951M 63.723M 58.443M 51.494M 43.522M 17.403M 4.227M 1.99M 1.923M 1.887M 1.75M 772K —
Net profit -265.939M -193.506M -80.736M -71.038M -6.553M -155.636M -86.372M -59.978M -63.386M -44.703M -39.748M -28.648M -13.317M
Free cash flow -216.893M -135.965M -76.321M -63.318M -66.744M -54.395M -79.816M -51.116M -58.725M -35.92M -35.521M -21.756M -13.032M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 12.14 8.54 4.46 2.81 6.97 20.7 3.95 3.98 4.45 8.37 9.37 23.52 —
Price performance 12m 0.42 0.91 0.59 -0.6 -0.66 4.24 -0.01 -0.11 -0.47 -0.11 -0.6 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 250,000 226,000 201,000 2.55M 12.3M 21.1M 21.3M 26.2M 32.4M 30.7M
↳ YoY growth +29.5% -9.6% -11.1% +1,167.7% +380.8% +72.5% +0.9% +22.8% +23.7% -5.4%
↳ 5y CAGR -4.3% +50.6% +129.4% +142.9% +148.3% +164.8% +66.3% +20.1%
Lease liabilities (USD) — — — 10M 8.91M 7.55M 10.3M 8.46M 7.28M 5.63M
Cash and deposits (USD) 32.9M 41.5M 54.1M 54.4M 228M 164M 102M 196M 392M 737M
Right-of-use assets (USD) — — — 6.66M 5.84M 4.87M 8.04M 6.47M 5.95M 4.64M
Cash flow detail
Operating cash flow (USD) -34M -50.5M -49.2M -77.6M -53.6M -65.6M -59.6M -70.2M -135M -205M
Purchases of property, plant and equipment (USD) -1.92M -8.25M -1.89M -2.24M -841,000 -1.19M -3.72M -6.09M -1.29M -12M
Change in receivables (cash effect) (USD) -57,000 24,000 25,000 -2.35M -9.7M -8.88M -190,000 -4.85M -6.21M 1.74M
Change in inventories (cash effect) (USD) 21,000 -9,000 -95,000 -737,000 -247,000 -49,000 -724,000 -331,000 -735,000 -524,000
Change in payables (cash effect) (USD) -159,000 932,000 -796,000 124,000 -452,000 1.8M -621,000 583,000 -318,000 -887,000
Interest paid (cash effect) (USD) -1.3M -1.46M -1.52M -2.3M -2.35M -1.93M -2.15M -5.46M -21.5M -9.03M
Share-based compensation (USD) 5.96M 7.32M 7.48M 8.76M 7.53M 15M 17M 17.8M 33.1M 43.2M
Operating cash flow before change in receivables (USD) -33.9M -50.5M -49.3M -75.2M -43.9M -56.7M -59.4M -65.4M -128M -207M
Free cash flow (OCF - PPE - intangibles) (USD) -35.9M -58.7M -51.1M -79.8M -54.4M -66.7M -63.3M -76.3M -136M -217M
Income detail
Research and development expense (USD) 27.1M 30.9M 36.9M 41.1M 28.7M 50.1M 53.5M 61.1M 128M 197M
↳ 5y CAGR +21.8% +28.5% +16.8% +1.5% +13.1% +11.6% +10.6% +25.4% +47.0%
Total comprehensive income (USD) -44.6M -63.4M -60M -86.4M — — — — — —
Comprehensive income to owners (USD) -44.6M -63.4M -60M -86.4M — — — — — —
Reported Mar 10, 2017 Mar 8, 2018 Mar 7, 2019 Mar 12, 2020 Mar 11, 2021 Feb 28, 2022 Mar 6, 2023 Mar 11, 2024 Mar 3, 2025 Feb 5, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

On November 9, 2026, Ocular Therapeutix, Inc. announced its financial results for the quarter ended September 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Election of Riad Sherif, M.D.

On November 6, 2026, the Board of Directors (the “Board”) of Ocular Therapeutix, Inc. (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee of the Board, elected Riad Sherif, M.D., to serve as a member of the Board, effective immediately. Dr. Sherif was designated as a Class I member of the Board to serve until the Company’s 2027 annual meeting of stockholders and thereafter until his successor is duly elected and qualified, or until his earlier death, resignation or removal.

Dr. Sherif, age 58, has served as the Chief Executive Officer and a member of the board of directors of Oculis Holding AG, a clinical-stage biopharmaceutical company, since December 2017. From June 2016 to September 2017, Dr. Sherif served as Entrepreneur in Residence at the Novartis Venture Fund. Previously, Dr. Sherif served as the Region President, Europe, Middle East and Africa, of Alcon, then the eye care division of Novartis AG, from March 2014 to May 2016. From January 2002 to March 2014, Dr.

November 6, 2026

PDF Version

BEDFORD, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to eight newly hired non-executive employees. The awards were made as an inducement material to each recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement equity awards were granted effective as of November 2, 2026, and consist of non-statutory stock option awards to purchase up to an aggregate of 35,775 shares of Ocular’s common stock and restricted stock unit awards representing the right to receive an aggregate of 11,725 shares of Ocular’s common stock. The stock option awards have an exercise price of $6.73 per share, equal to the closing price of Ocular’s common stock on The Nasdaq Global Market on the effective date of grant. Each of the stock option awards has a ten-year term and vests over four years, with 25% of the original number of shares for each award vesting on the one-year anniversary of the applicable recipient’s commencement of employment, and the remainder vesting in equal monthly installments over the three years after such date, subject to the recipient’s continued service to Ocular through the applicable vesting dates. Each of the restricted stock unit awards vests over three years, in equal annual installments on the first, second and third anniversaries of the date of grant, subject to the recipient’s continued service to Ocular through the applicable vesting dates.

The inducement equity awards are subject to the terms and conditions of the award agreements covering the grants and Ocular’s 2019 Inducement Stock Incentive Plan.

About Ocular Therapeutix, Inc. Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR). Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.

Follow the Company on its website, LinkedIn, or X.

DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media Ocular Therapeutix, Inc. Bill Slattery Vice President, Investor Relations [email protected]

Company Logo

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer. More information

Allow All

Manage Consent Preferences

Performance Cookies

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

Cookies Details

Targeting Cookies

Targeting Cookies

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Cookies Details

Functional Cookies

Functional Cookies

These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

Cookies Details

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Cookies Details

Cookie List

Clear

  • checkbox label label

Apply Cancel

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Reject All

Powered by Onetrust

Prompts

Ocular Therapeutix, Inc. (ticker OCUL), listed in United States.

Company History

Date Change Detail
Jan 12, 2011 Renamed I-THERAPEUTIX INC → OCULAR THERAPEUTIX, INC

ETFs Holding Ocular Therapeutix, Inc.

ETF Weight in ETF Shares Market value As of
SURI 0.72% 81,051 $ 487.927K Nov 17, 2026
RESM 0.09% 344 $ 3,378.08 Jun 30, 2026
DFAS 0.02% 1,240,160 $ 7.788M Nov 12, 2026
MSSM 0.01% 7,093 $ 74.406K Aug 31, 2026
DXUV 0.01% 64,169 $ 402.981K Nov 12, 2026
DFAC 0.00% 504,518 $ 3.168M Nov 12, 2026
DCOR 0.00% 154,488 $ 970.185K Nov 12, 2026
DFUS 0.00% 55,986 $ 351.592K Nov 12, 2026
DFAU 0.00% 30,772 $ 193.248K Nov 12, 2026